BioTuesdays

Author - Abby Hardy

Profound Medical Logo
Markets

CIBC starts Profound Medical at OP, PT $3.50

CIBC World Markets initiated coverage of Profound Medical (TSXV:PRN; OTCQX:PRFMF) with an “outperformer” rating and 12-to-18-month price target of $3.50. The stock closed at 85 cents on Nov. 15. Analyst Prakash Gowd...

November 16, 2017
IRIDEX
Markets

Roth resumes coverage of IRIDEX at buy, PT $13

Roth Capital Partners resumed coverage of IRIDEX (NASDAQ:IRIX) with a “buy” rating and $13 price target after the company reported modest upside to Roth’s prior revenue targets for the third quarter. “Further, the...

November 3, 2017
Syros-Logo
Markets

Roth starts Syros at neutral, PT $16

Roth Capital Partners launched coverage of Syros Pharmaceuticals (NASDAQ:SYRS) with a “neutral” rating and price target of $16. The stock closed at $16.51 on Oct.23. “Syros is maturing into a solid company, but value...

October 24, 2017
GlycoMimetics
Markets

Roth starts GlycoMimetics at buy, PT $25

Roth Capital Partners initiated coverage of GlycoMimetics (NASDAQ:GLYC) with a “buy” rating and $25 price target. The stock closed at $10.52 on Oct. 23. “Our bull thesis on GlycoMimetics is driven by the GMI-1271...

October 24, 2017
Nightstar Therapeutics
Markets

Leerink starts Nightstar at OP

Leerink initiated coverage of Nightstar Therapeutics (NASDAQ:NITE) with an “outperform” rating and $25 price target. The stock closed at $19 on Oct. 20. Nightstar is harnessing the potentially curative properties of...

October 23, 2017
Galectin Therapeutics
Markets

Roth starts Galectin at buy

Roth Capital Partners initiated coverage of Galectin Therapeutics (NASDAQ:GALT) with a “buy” rating and a 12-month price target of $8. The stock closed at $2.51 on Oct. 18. “Our rating on Galectin shares is based on our...

October 19, 2017
Ardelyx
Markets

Leerink resumes coverage of Ardelyx at OP

Leerink resumed coverage of Ardelyx (NASDAQ:ARDX) with an “outperform” rating and $13 price target. The stock closed at $6.40 on Oct. 16. Analyst Seamus Fernandez writes that in the last nine months, the clinical...

October 17, 2017
BioTime
Markets

BioTime prices $25-million stock offering

BioTime (NYSE MKT, TASE: BTX) priced a public offering of 9,615,385 common shares at a price of $2.60 each for gross proceeds of about $25-million. The offering is expected to close on Oct. 17. BioTime also granted...

October 13, 2017
Heska-Corporation-Logo
Markets

Canaccord starts Heska at buy

Canaccord Genuity initiated coverage of Heska (NASDAQ:HSKA) with a “buy” rating and price target of $115. The stock closed at $91.38 on Oct. 4. “Our survey work and checks suggest ongoing attractive market trends in...

October 5, 2017
Zogenix
Markets

Analysts up Zogenix to OP, double price target to $55

William Blair upgraded Zogenix (NASAQ:ZGNX) to “outperform” and Stifel more than doubled its price target to $55 from $26 after the company unveiled strongly positive Phase 3 data for ZX008 (fenfluramine) in Dravet...

September 29, 2017